Skip to main content
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel
Journal cover image

Molecular staging of lung and esophageal cancer.

Publication ,  Journal Article
Lau, CL; Moore, M-BH; Brooks, KR; D'Amico, TA; Harpole, DH
Published in: Surg Clin North Am
June 2002

In both esophageal and NSCLC, the TNM stage at diagnosis remains the most important determinant of survival. Significant research to investigate the biology of NSCLC and esophageal carcinoma is ongoing, and the roles of proto-oncogenes, tumor suppressor genes, angiogenic factors, extracellular matrix proteases, and adhesion molecules are being elucidated. While evidence is accumulating that various markers are involved in NSCLC and esophageal tumor virulence, the current studies are compromised by small sample sizes, heterogeneous populations, and variations in techniques. Large prospective studies with homogenous groups designed to evaluate the role of these various markers should clarify their potential involvement in NSCLC and esophageal cancer. Identification of occult micrometastases in lymph nodes and bone marrow using immunohistochemical techniques and rt-PCR is intriguing. These techniques are promising as a method to more accurately stage patients, and therefore to predict outcomes and to determine therapies. Perhaps the most promising area of research is the development of novel drugs whose mechanism of action targets the pathways of various molecular markers. Molecular biologic substaging offers an opportunity to individualize a chemotherapeutic regimen based on the molecular profile of the tumor, thus providing the potential for improved outcomes with less morbidity in patients with both NSCLC and esophageal cancer.

Duke Scholars

Published In

Surg Clin North Am

DOI

ISSN

0039-6109

Publication Date

June 2002

Volume

82

Issue

3

Start / End Page

497 / 523

Location

United States

Related Subject Headings

  • Surgery
  • Neoplasm Staging
  • Lung Neoplasms
  • Humans
  • Genetic Markers
  • Esophageal Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lau, C. L., Moore, M.-B., Brooks, K. R., D’Amico, T. A., & Harpole, D. H. (2002). Molecular staging of lung and esophageal cancer. Surg Clin North Am, 82(3), 497–523. https://doi.org/10.1016/s0039-6109(02)00024-5
Lau, Christine L., Mary-Beth H. Moore, Kelly R. Brooks, Thomas A. D’Amico, and David H. Harpole. “Molecular staging of lung and esophageal cancer.Surg Clin North Am 82, no. 3 (June 2002): 497–523. https://doi.org/10.1016/s0039-6109(02)00024-5.
Lau CL, Moore M-BH, Brooks KR, D’Amico TA, Harpole DH. Molecular staging of lung and esophageal cancer. Surg Clin North Am. 2002 Jun;82(3):497–523.
Lau, Christine L., et al. “Molecular staging of lung and esophageal cancer.Surg Clin North Am, vol. 82, no. 3, June 2002, pp. 497–523. Pubmed, doi:10.1016/s0039-6109(02)00024-5.
Lau CL, Moore M-BH, Brooks KR, D’Amico TA, Harpole DH. Molecular staging of lung and esophageal cancer. Surg Clin North Am. 2002 Jun;82(3):497–523.
Journal cover image

Published In

Surg Clin North Am

DOI

ISSN

0039-6109

Publication Date

June 2002

Volume

82

Issue

3

Start / End Page

497 / 523

Location

United States

Related Subject Headings

  • Surgery
  • Neoplasm Staging
  • Lung Neoplasms
  • Humans
  • Genetic Markers
  • Esophageal Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • 3202 Clinical sciences
  • 1103 Clinical Sciences